Adjuvant selenium supplementation in the form of sodium selenite in postoperative critically ill patients with severe sepsis.
BACKGROUND
Plasma selenium (Se) concentrations are reduced in critically ill surgical patients, and lower plasma Se concentrations are associated with worse outcomes. We investigated whether adjuvant Se supplementation in the form of sodium selenite could improve outcomes in surgical patients with sepsis.


METHODS
In this retrospective study, all adult patients admitted to a 50-bed surgical ICU with severe sepsis between January 2004 and April 2010 were included and analysed according to whether they had received adjuvant Se supplementation, which was given at the discretion of the attending physician. When prescribed, Se was administered in the form of sodium selenite pentahydrate (Na2SeO3∙5H2O), in which 100 μg of Se corresponds to 333 μg of sodium selenite. A bolus of sodium selenite corresponding to 1,000 μg of Se was injected intravenously through a central venous line for 30 minutes, followed by infusion of 1,000 μg/day for 24 hours for 14 days until ICU discharge or death. We performed logistic regression analysis to investigate the impact of adjuvant Se supplementation on hospital mortality.


RESULTS
Adjuvant Se was administered to 413 (39.7%) of the 1,047 patients admitted with severe sepsis. Age and sex were similar between patients who received adjuvant Se and those who did not. Compared with patients who did not receive adjuvant Se supplementation, patients who did had higher scores on the Simplified Acute Physiology Score II, a greater prevalence of cancer upon admission to the ICU and were more commonly admitted after abdominal surgery. Compared with patients who did not receive adjuvant Se, patients who did had higher hospital mortality rates (46% versus 39.1%; P = 0.027), and longer median (interquartile range (IQR)) ICU stays (15 days (6 to 24) versus 11 days (4 to 24); P = 0.01) and hospital lengths of stay (33 days (21 to 52) versus 28 days (17 to 46); P = 0.001). In multivariable analysis, adjuvant Se supplementation was not independently associated with favourable outcome (odds ratio = 1.19, 95% confidence interval = 0.86 to 1.65; P = 0.288).


CONCLUSIONS
In this retrospective analysis of a large cohort of surgical ICU patients with severe sepsis, adjuvant Se supplementation in the form of sodium selenite had no impact on in-hospital death rates after adjustment for confounders.
Yasser
Y
Sakr
Vivian P L
VP
Maia
Clesar
C
Santos
Julia
J
Stracke
Mohamed
M
Zeidan
Ole
O
Bayer
Konrad
K
Reinhart
D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant / Q000401:mortality / Q000639:trends; D015331:Cohort Studies; D016638:Critical Illness / Q000401:mortality / Q000628:therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods*; D012189:Retrospective Studies; D012643:Selenium / Q000008:administration & dosage*; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D018038:Sodium Selenite / Q000008:administration & dosage*
D012643:Selenium; D018038:Sodium Selenite